Armata Pharmaceuticals Stock Price To Earning
| ARMP Stock | USD 2.29 0.04 1.78% |
Armata Pharmaceuticals fundamentals help investors to digest information that contributes to Armata Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Armata Stock. The fundamental analysis module provides a way to measure Armata Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Armata Pharmaceuticals stock.
Armata | Price To Earning |
Armata Pharmaceuticals Company Price To Earning Analysis
Armata Pharmaceuticals' Price to Earnings ratio is typically used for current valuation of a company and is one of the most popular ratios that investors monitor daily. Holding a low PE stock is less risky because when a company's profitability falls, it is likely that earnings will also go down as well. In other words, if you start from a lower position, your downside risk is limited. There are also some investors who believe that low Price to Earnings ratio reflects the low pricing because a given company is in trouble. On the other hand, a higher PE ratio means that investors are paying more for each unit of profit.
Current Armata Pharmaceuticals Price To Earning | (1.65) X |
Most of Armata Pharmaceuticals' fundamental indicators, such as Price To Earning, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Armata Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Armata Price To Earning Driver Correlations
Understanding the fundamental principles of building solid financial models for Armata Pharmaceuticals is extremely important. It helps to project a fair market value of Armata Stock properly, considering its historical fundamentals such as Price To Earning. Since Armata Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Armata Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Armata Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
Generally speaking, the Price to Earnings ratio gives investors an idea of what the market is willing to pay for the company's current earnings.
| Competition |
Armata Retained Earnings
Retained Earnings |
|
Based on the latest financial disclosure, Armata Pharmaceuticals has a Price To Earning of -1.645 times. This is 106.37% lower than that of the Biotechnology sector and 133.37% lower than that of the Health Care industry. The price to earning for all United States stocks is 105.73% higher than that of the company.
Armata Price To Earning Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Armata Pharmaceuticals' direct or indirect competition against its Price To Earning to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Armata Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Armata Pharmaceuticals by comparing valuation metrics of similar companies.Armata Pharmaceuticals is currently under evaluation in price to earning category among its peers.
Armata Pharmaceuticals Current Valuation Drivers
We derive many important indicators used in calculating different scores of Armata Pharmaceuticals from analyzing Armata Pharmaceuticals' financial statements. These drivers represent accounts that assess Armata Pharmaceuticals' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Armata Pharmaceuticals' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 25.4M | 49.0M | 132.1M | 42.5M | 116.9M | 122.7M | |
| Enterprise Value | 22.3M | 52.5M | 159.8M | 76.5M | 223.7M | 234.9M |
Armata Pharmaceuticals ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Armata Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Armata Pharmaceuticals' managers, analysts, and investors.Environmental | Governance | Social |
Armata Fundamentals
| Return On Equity | -34.39 | ||||
| Return On Asset | -0.25 | ||||
| Operating Margin | (11.31) % | ||||
| Current Valuation | 204.6 M | ||||
| Shares Outstanding | 36.18 M | ||||
| Shares Owned By Insiders | 70.24 % | ||||
| Shares Owned By Institutions | 3.82 % | ||||
| Number Of Shares Shorted | 4.54 K | ||||
| Price To Earning | (1.65) X | ||||
| Price To Book | 4.06 X | ||||
| Price To Sales | 21.89 X | ||||
| Revenue | 4.53 M | ||||
| Gross Profit | (29.51 M) | ||||
| EBITDA | (39.92 M) | ||||
| Net Income | (69.05 M) | ||||
| Cash And Equivalents | 36.98 M | ||||
| Cash Per Share | 1.02 X | ||||
| Total Debt | 120.37 M | ||||
| Debt To Equity | 0.73 % | ||||
| Current Ratio | 5.59 X | ||||
| Book Value Per Share | (0.89) X | ||||
| Cash Flow From Operations | (47.42 M) | ||||
| Short Ratio | 0.86 X | ||||
| Earnings Per Share | (1.15) X | ||||
| Target Price | 7.0 | ||||
| Number Of Employees | 66 | ||||
| Beta | 0.81 | ||||
| Market Capitalization | 81.41 M | ||||
| Total Asset | 98.36 M | ||||
| Retained Earnings | (308.82 M) | ||||
| Working Capital | 2.69 M | ||||
| Current Asset | 4.48 M | ||||
| Current Liabilities | 4.08 M | ||||
| Net Asset | 98.36 M |
About Armata Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Armata Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Armata Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Armata Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Armata Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Armata Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Armata Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Armata Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Armata Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Armata Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Armata Pharmaceuticals to buy it.
The correlation of Armata Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Armata Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Armata Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Armata Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Armata Stock Analysis
When running Armata Pharmaceuticals' price analysis, check to measure Armata Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Armata Pharmaceuticals is operating at the current time. Most of Armata Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Armata Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Armata Pharmaceuticals' price. Additionally, you may evaluate how the addition of Armata Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.